•ImmunityBio announced the resubmission of a supplemental Biologics License Application (sBLA) for ANKTIVA plus BCG for the treatment of papillary NMIBC.
•The FDA acknowledged receipt of the filing following a review of additional data provided by the company in February 2026.
•The treatment targets approximately 70% of NMIBC patients who present with papillary disease.
•Relmada Therapeutics (RLMD) announced an oversubscribed $160.0 million private investment in public equity (PIPE) financing.
•Relmada's financing included participation from major institutions like Venrock Healthcare Capital Partners, Janus Henderson Investors, and RA Capital Management.
•PyroGenesis (PYR) announced its intention to complete a non-brokered private placement to raise up to $1,000,000 at $0.54 per unit.
